Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Identifieur interne : 000D16 ( Main/Exploration ); précédent : 000D15; suivant : 000D17Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Auteurs : Otto Hartman [Finlande] ; Petri T. Kovanen [Finlande] ; Jukka Lehtonen [Finlande] ; Kari K. Eklund [Finlande] ; Juha Sinisalo [Finlande]Source :
- European heart journal. Cardiovascular pharmacotherapy [ 2055-6845 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- usage thérapeutique : Antirhumatismaux, Hydroxychloroquine.
- étiologie : Athérosclérose.
- Athérosclérose, Humains, Infarctus du myocarde, Méthode en double aveugle, Projets pilotes, Prévention secondaire, Récidive.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antirheumatic Agents, Hydroxychloroquine.
- complications : Myocardial Infarction.
- etiology : Atherosclerosis.
- methods : Secondary Prevention.
- prevention & control : Atherosclerosis.
- Double-Blind Method, Humans, Pilot Projects, Recurrence.
Abstract
Inflammation of the arterial wall plays a central role in the pathogenesis of atherosclerosis. Among patients with rheumatic diseases, anti-rheumatic medication reduces the incidence of cardiovascular (CV) diseases, but only few studies have addressed their cardioprotective effects on patients with no rheumatic diseases. Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. In addition to its anti-inflammatory properties, HCQ reduces cholesterol levels and the risk of type II diabetes, and has also anti-platelet effects.
DOI: 10.1093/ehjcvp/pvw035
PubMed: 28025216
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000184
- to stream PubMed, to step Curation: 000184
- to stream PubMed, to step Checkpoint: 000167
- to stream Ncbi, to step Merge: 000367
- to stream Ncbi, to step Curation: 000367
- to stream Ncbi, to step Checkpoint: 000367
- to stream Main, to step Merge: 000D16
- to stream Main, to step Curation: 000D16
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.</title><author><name sortKey="Hartman, Otto" sort="Hartman, Otto" uniqKey="Hartman O" first="Otto" last="Hartman">Otto Hartman</name><affiliation wicri:level="1"><nlm:affiliation>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS</wicri:regionArea><wicri:noRegion>00029 HUS</wicri:noRegion></affiliation></author><author><name sortKey="Kovanen, Petri T" sort="Kovanen, Petri T" uniqKey="Kovanen P" first="Petri T" last="Kovanen">Petri T. Kovanen</name><affiliation wicri:level="1"><nlm:affiliation>Wihuri Research Institute, Biomedicum Helsinki, Haartmaninkatu 8, Helsinki 00290, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Wihuri Research Institute, Biomedicum Helsinki, Haartmaninkatu 8, Helsinki 00290</wicri:regionArea><wicri:noRegion>Helsinki 00290</wicri:noRegion></affiliation></author><author><name sortKey="Lehtonen, Jukka" sort="Lehtonen, Jukka" uniqKey="Lehtonen J" first="Jukka" last="Lehtonen">Jukka Lehtonen</name><affiliation wicri:level="1"><nlm:affiliation>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS</wicri:regionArea><wicri:noRegion>00029 HUS</wicri:noRegion></affiliation></author><author><name sortKey="Eklund, Kari K" sort="Eklund, Kari K" uniqKey="Eklund K" first="Kari K" last="Eklund">Kari K. Eklund</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Rheumatology, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Helsinki</wicri:regionArea><wicri:noRegion>Helsinki</wicri:noRegion></affiliation></author><author><name sortKey="Sinisalo, Juha" sort="Sinisalo, Juha" uniqKey="Sinisalo J" first="Juha" last="Sinisalo">Juha Sinisalo</name><affiliation wicri:level="1"><nlm:affiliation>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS</wicri:regionArea><wicri:noRegion>00029 HUS</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28025216</idno><idno type="pmid">28025216</idno><idno type="doi">10.1093/ehjcvp/pvw035</idno><idno type="wicri:Area/PubMed/Corpus">000184</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000184</idno><idno type="wicri:Area/PubMed/Curation">000184</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000184</idno><idno type="wicri:Area/PubMed/Checkpoint">000167</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000167</idno><idno type="wicri:Area/Ncbi/Merge">000367</idno><idno type="wicri:Area/Ncbi/Curation">000367</idno><idno type="wicri:Area/Ncbi/Checkpoint">000367</idno><idno type="wicri:Area/Main/Merge">000D16</idno><idno type="wicri:Area/Main/Curation">000D16</idno><idno type="wicri:Area/Main/Exploration">000D16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.</title><author><name sortKey="Hartman, Otto" sort="Hartman, Otto" uniqKey="Hartman O" first="Otto" last="Hartman">Otto Hartman</name><affiliation wicri:level="1"><nlm:affiliation>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS</wicri:regionArea><wicri:noRegion>00029 HUS</wicri:noRegion></affiliation></author><author><name sortKey="Kovanen, Petri T" sort="Kovanen, Petri T" uniqKey="Kovanen P" first="Petri T" last="Kovanen">Petri T. Kovanen</name><affiliation wicri:level="1"><nlm:affiliation>Wihuri Research Institute, Biomedicum Helsinki, Haartmaninkatu 8, Helsinki 00290, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Wihuri Research Institute, Biomedicum Helsinki, Haartmaninkatu 8, Helsinki 00290</wicri:regionArea><wicri:noRegion>Helsinki 00290</wicri:noRegion></affiliation></author><author><name sortKey="Lehtonen, Jukka" sort="Lehtonen, Jukka" uniqKey="Lehtonen J" first="Jukka" last="Lehtonen">Jukka Lehtonen</name><affiliation wicri:level="1"><nlm:affiliation>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS</wicri:regionArea><wicri:noRegion>00029 HUS</wicri:noRegion></affiliation></author><author><name sortKey="Eklund, Kari K" sort="Eklund, Kari K" uniqKey="Eklund K" first="Kari K" last="Eklund">Kari K. Eklund</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Rheumatology, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Helsinki</wicri:regionArea><wicri:noRegion>Helsinki</wicri:noRegion></affiliation></author><author><name sortKey="Sinisalo, Juha" sort="Sinisalo, Juha" uniqKey="Sinisalo J" first="Juha" last="Sinisalo">Juha Sinisalo</name><affiliation wicri:level="1"><nlm:affiliation>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, PL 340, 00029 HUS</wicri:regionArea><wicri:noRegion>00029 HUS</wicri:noRegion></affiliation></author></analytic><series><title level="j">European heart journal. Cardiovascular pharmacotherapy</title><idno type="eISSN">2055-6845</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (therapeutic use)</term><term>Atherosclerosis (etiology)</term><term>Atherosclerosis (prevention & control)</term><term>Double-Blind Method</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Myocardial Infarction (complications)</term><term>Pilot Projects</term><term>Recurrence</term><term>Secondary Prevention (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antirhumatismaux (usage thérapeutique)</term><term>Athérosclérose ()</term><term>Athérosclérose (étiologie)</term><term>Humains</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Infarctus du myocarde ()</term><term>Méthode en double aveugle</term><term>Projets pilotes</term><term>Prévention secondaire ()</term><term>Récidive</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Myocardial Infarction</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Atherosclerosis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Secondary Prevention</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Atherosclerosis</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Athérosclérose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Humans</term><term>Pilot Projects</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Athérosclérose</term><term>Humains</term><term>Infarctus du myocarde</term><term>Méthode en double aveugle</term><term>Projets pilotes</term><term>Prévention secondaire</term><term>Récidive</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inflammation of the arterial wall plays a central role in the pathogenesis of atherosclerosis. Among patients with rheumatic diseases, anti-rheumatic medication reduces the incidence of cardiovascular (CV) diseases, but only few studies have addressed their cardioprotective effects on patients with no rheumatic diseases. Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. In addition to its anti-inflammatory properties, HCQ reduces cholesterol levels and the risk of type II diabetes, and has also anti-platelet effects.</div></front></TEI><affiliations><list><country><li>Finlande</li></country></list><tree><country name="Finlande"><noRegion><name sortKey="Hartman, Otto" sort="Hartman, Otto" uniqKey="Hartman O" first="Otto" last="Hartman">Otto Hartman</name></noRegion><name sortKey="Eklund, Kari K" sort="Eklund, Kari K" uniqKey="Eklund K" first="Kari K" last="Eklund">Kari K. Eklund</name><name sortKey="Kovanen, Petri T" sort="Kovanen, Petri T" uniqKey="Kovanen P" first="Petri T" last="Kovanen">Petri T. Kovanen</name><name sortKey="Lehtonen, Jukka" sort="Lehtonen, Jukka" uniqKey="Lehtonen J" first="Jukka" last="Lehtonen">Jukka Lehtonen</name><name sortKey="Sinisalo, Juha" sort="Sinisalo, Juha" uniqKey="Sinisalo J" first="Juha" last="Sinisalo">Juha Sinisalo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28025216
|texte= Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28025216" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |